The vBlocT2D Study
vBloc Therapy for Obese Subjects With Type 2 Diabetes- A Randomized Controlled Clinical Trial
Overall aim: To demonstrate that weight loss through vBloc Therapy in combination with usual care will achieve better glycemic control for patients with obesity and type 2 diabetes than usual care alone.
Duration: Participants will be asked to participate in a 12 month study that involves a baseline visit and research follow-up visits at 3, 6, 9, and 12 months.
Sample Size: 60 participants will be enrolled in the study. Of these, 30 will be randomized to vBloc therapy and 30 will be randomized to usual care.
研究概览
详细说明
研究类型
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
Harbor City、California、美国、90710
- Kaiser Permanente South Bay Medical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND
- Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND
- Age 18 years or older, AND
- Body mass index (BMI) 35-45 kg/m2 inclusive, AND
- Attempt and failed diet, exercise and behavioral modification program within past five years,
Exclusion Criteria:
- Use of GLP-1 receptor agonists for diabetes currently or within past 6 months
- Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators))
- Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body)
- Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation
- Previous bariatric or upper GI surgery
- Excessive alcohol intake
- Current smokers or smoking cessation in prior 3 months
- An underlying disease known to have important effects on glucose metabolism
- Active infections
- Anemia (Hemoglobin <11g/dl in women, <12 g/dl in men) or known coagulopathy
- Chronic kidney disease manifest as serum creatinine >2.0 mg/dl
- Diabetic retinopathy requiring photocoagulation therapy
- Symptomatic diabetic gastroparesis
- Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure
- Cirrhosis of the liver, portal hypertension, or esophageal varices
- Symptomatic esophageal reflux
Conditions or behaviors likely to affect the conduct of the vBloc Study
- Unable or unwilling to give informed consent
- Unable to adequately communicate with clinic staff
- Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study
- Likely to move away from participating clinic in next 2 years
- Current (or anticipated) pregnancy and lactation.
- Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study
- Weight loss >7% in past two months for any reason except postpartum weight loss.
- Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:vBloc Therapy + Usual Care for Type 2 Diabetes
|
The vBloc device will be placed using a laparoscopic procedure.
The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. .
Pre-operative testing will be conducted per surgeon's evaluation.
Participants will receive weight management education according to the vBloc Therapy protocol.
|
|
无干预:Usual Care for Type 2 Diabetes
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Mean reduction in HbA1c
大体时间:at 12 months after baseline
|
at 12 months after baseline
|
合作者和调查者
调查人员
- 首席研究员:Anny Xiang, PhD、Kaiser Permanente
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.